Development and Validation of a Novel Prognostic Nomogram Based on Platelet and CD8+T Cell Counts in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis
DOI: https://doi.org/10.2147/jhc.s452688
2024-06-08
Journal of Hepatocellular Carcinoma
Abstract:Wanxin Shi, 1, 2, &ast Huiwen Yan, 1, &ast Xiaoli Liu, 1 Lihua Yu, 1 Yuqing Xie, 1 Yuan Wu, 1 Yuling Liang, 1 Zhiyun Yang 1 1 Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China; 2 First Clinical Medical College, Beijing University of Chinese Medicine, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhiyun Yang, Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015, People's Republic of China, Tel/Fax +86-10-84322148, Email Purpose: Portal vein tumor thrombosis (PVTT) is one of the hallmarks of advanced Hepatocellular carcinoma (HCC). Platelet (PLT) function parameters and CD8 + T cells (CD8 + Ts) play an important role in HCC progression and metastasis. This study is committed to establishing an efficient prognosis prediction model and exploring the combined effect of PLT and CD8 + Ts on PVTT prognosis. Patients and Methods: This retrospective study collected 932 HCC patients with PVTT from 2007 to 2017 and randomly divided them into a training cohort (n = 656) and a validation cohort (n = 276). We performed multivariable Cox and Elastic-net regression analysis, constructed a nomogram and used Kaplan–Meier survival curves to compare overall survival and progression-free survival rates in different substrata. Relationships between indicators involved were also analyzed. Results: We found tumor number, size, treatment, PLT, γ-glutamyl transferase, alpha-fetoprotein, mean platelet volume, and CD8 + Ts were related to the 5-year OS of patients with PVTT, and established a nomogram. The area under the receiver operating characteristic curve (AUCs) for predicting the 1-year OS rates were 0.767 and 0.794 in training and validation cohorts. The calibration curve and decision curve indicated its predictive consistency and strong clinical utility. We also found those with low PLT (< 100&ast10^9/L) and high CD8 + Ts (> 320 cells/μL) had a better prognosis. Conclusion: We established a well-performing prognostic model for PVTT based on platelet functional parameters and CD8 + Ts, and found that PT-8 formed by PLT and CD8 + Ts was an excellent predictor of the prognosis of PVTT. Keywords: hepatocellular carcinoma, portal vein tumor thrombus, platelet, CD8+T cells counts, prognostic model, correlation analysis Hepatocellular carcinoma (HCC) is one of the major diseases that seriously endangers human life and health. According to the latest global cancer burden data released by WHO, the incidence and mortality of HCC rank sixth and fourth among malignant tumors, respectively. 1 Due to the biological characteristics of liver cancer and the anatomical characteristics of the liver, HCC easily invades intrahepatic blood vessels, especially the portal vein system. In China, the incidence rate of portal vein tumor thrombosis (PVTT) is as high as 44–62.2%. Without treatment, the median survival time of HCC patients with PVTT is only 2.7–4 months. 2 PVTT progresses rapidly and can lead to serious complications such as portal hypertension, hepatic jaundice, and refractory ascites. Therefore, the treatment strategy for PVTT has become a global medical problem. Currently, Barcelona Clinic Liver Cancer (BCLC), Child-Pugh and Model for end-stage liver disease (MELD), etc. are often used to evaluate the prognosis of HCC patients. 3 PVTT, as a marker of advanced liver cancer, is also a major factor affecting the prognosis of HCC. However, it is still unclear whether the prognostic indicators of HCC are still applicable to PVTT. Multiple studies have shown that platelets are closely related to the occurrence and development of tumors and have certain prognostic predictive value. 4–7 Decades ago, lots of scientists demonstrated that platelets could promote tumor vascular invasion and metastasis. 8,9 Platelets exercise a function as if it were a double-edged sword. Recent studies have also identified thrombocytopenia as a risk factor for recurrence and survival in patients with HCC after hepatectomy, which explains that platelet count reflects liver function to a certain extent, and thrombocytopenia implies a poor prognosis. 10 In summary, platelets play different roles in liver cancer at different stages. In addition, immune status has always been considered a prognostic factor for patients at all stages, especially for advanced liver cancer. 11 There is a correlation -Abstract Truncated-
oncology